Stimulating engineered T cells with a powerful immunogen enhances their ability to kill tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pardoll, D.M. Nat. Rev. Immunol. 2, 227–238 (2002).
Kershaw, M.H., Westwood, J.A. & Hwu, P. Nat. Biotechnol. 20, 1221–1227, (2002).
Dudley, M.E. et al. Science 298, 850–854 (2002).
Yee, C. et al. Proc. Natl. Acad. Sci. USA, in press (2002).
Liu, X., Peralta, E.A., Ellenhorn, J.D. & Diamond, D.J. Cancer Res. 60, 693–701 (2000).
Gross, G., Waks, T. & Eshhar, Z. Proc. Natl. Acad. Sci. USA. 86, 10024–10028 (1989).
Irving, B.A. & Weiss, A. Cell. 64, 891–901 (1991).
Eshhar, Z., Waks, T., Gross, G. & Schindler, D.G. Proc. Natl. Acad. Sci. USA. 90, 720–724 (1993).
Hwu, P. et al. J. Exp. Med. 178, 361–366 (1993).
Schwartz, R.H. Cell 71, 1065–1068 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pardoll, D. Tumor reactive T cells get a boost. Nat Biotechnol 20, 1207–1208 (2002). https://doi.org/10.1038/nbt1202-1207
Issue Date:
DOI: https://doi.org/10.1038/nbt1202-1207
This article is cited by
-
Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen
Cancer Immunology, Immunotherapy (2007)